# Bamboo & Health NarxCare®

NarxCare Application Overview

> September 2023 Version 1.0



9901 Linn Station Road, Suite 500 | Louisville, KY 40223 | bamboohealth.com

# **Table of Contents**

NarxCare Application	4
Introduction to NarxCare	4
Why NarxCare?	4
How Does NarxCare Work?	4
Who Has Access to NarxCare?	5
How is NarxCare Used in Therapy Management?	5
NarxCare Layout	5
NarxCare Overview	8
Header and Patient Identifying Information	8
Prescription Detail	8
Provider and Pharmacy Detail	9
Rx Graph	9
Other graphs	10
Download Options	12
Other Tools/Metrics	12
Resources	
MOUD Providers	13
PDMP & CDC Resources	13
Indicators and Scores	14
Additional Indicators	14
Additional State Indicators	15
Narx Scores	
How are Narx Scores Used?	17
Narx Score Calculations and Metrics	17
Narx Score Algorithm	
Score Computation	22
Overdose Risk Score	25
ORS Intended Use	25
ORS Algorithm Development	25
Additional ORS External Validation	26

ORS Data Inputs	27
Additional Information on ORS	
Document Information	30
Disclaimer	
Change Log	

# NarxCare Application

NarxCare is an application that provides a set of tools to support clinicians' analysis of controlled substance data from government managed and regulated Prescription Drug Monitoring Programs (PDMPs)<sup>1</sup>.

Informed prescribing practices must be part of a multi-dimensional response to the ongoing opioid epidemic. The NarxCare application automatically analyzes PDMP data and delivers scores and visualizations of usage patterns based on the data, to further enable informed prescribing and dispensing practices. The NarxCare application is user-friendly, easily integrated into a patient's electronic medical record, and interoperable with other PDMPs. This document provides an overview of the NarxCare application and a breakdown of the report and analytics tools.

# Why NarxCare?

NarxCare offers a representation of PDMP data in an interactive format to help clinicians<sup>2</sup>, and care teams quickly and easily access and interpret data to aid in their controlled substance<sup>3</sup> therapy management.

With the NarxCare application, healthcare providers have access to all the features and functions of NarxCare enabled by their PDMP Administrator with a consistent look and feel for all users who access the solution. Furthermore, NarxCare delivery is enabled within Electronic Health Records (EHR) and Pharmacy Management Systems for those prescribers and dispensers who choose to access NarxCare through integration within their healthcare IT system.

# How Does NarxCare Work?

NarxCare aggregates historical and active PDMP data and presents color-coded, interactive, visual representations of the PDMP data. In addition, NarxCare has **Other Tools/Metrics** that contain a **Resources** dropdown menu where you can find Medications for Opioid Use Disorder (MOUDs) providers and CDC educational resources. These resources can be used by clinicians as an aid to help patients.

<sup>&</sup>lt;sup>1</sup> When used in this document, unless the context requires otherwise, "PDMP" refers to the applicable state, territory, locality, or other government PDMP for the authorized user.

<sup>&</sup>lt;sup>2</sup> When used in this document, the term "clinician" refers to any prescriber or dispenser authorized user.

<sup>&</sup>lt;sup>3</sup> When used in this document, the term "controlled substance" refers to any federal or state controlled substance, as well as any other PDMP-reportable drugs.

# Who Has Access to NarxCare?

NarxCare is available to all authorized end users, whether they are accessing NarxCare via the web portal, an integrated EHR system, or pharmacy software.

## How is NarxCare Used in Therapy Management?

The information provided in NarxCare is intended to support clinicians' controlled substance therapy management activities. For example, with respect to information provided in NarxCare that indicates increased overdose risk potential, the information may be helpful in prompting consideration of strategies to mitigate risk of an overdose, if warranted, based on the specific patient context and the clinician's professional judgement. However, none of the information presented should be used as sole justification for providing or refusing to provide medications.

# NarxCare Layout

The NarxCare application displays PDMP data in the form of tiles. The following layout provides common tiles you may see in your interface.

Header	[First Name] [Last Name], [Age] [Patient S Date of Brit: [0000000000] [Steet Name, County, State, Zip Code] Status of State	
	NarxCare®	
	Report generated on 01/16/2023. Report Date Range: 01/16/	2021 - 01/16/2023 D FDF Report Z Export
Scores &	Narx Scores	Overdose Risk Score State Indicators (3)
Indicators	Narcotic Sedative Stimu	Iant I >= 4 opioid or sedative dispensing pharmacies in any 90
	791 541 00	0 730 Solution in the last 2 years
		(Range 000-999)
		>100 MME total and 40 MME/day average
	Explanation and Gu	idance Explanation and Guidance
		Details
RX Graph	RX Graph	
lot diupii	Narcotic V Buprenorphine V Sedative V Stimulan	et 🔽 Other
	All Prescribere	
	Prescribers	
	Prescriber #16 Prescriber #15	
	Prescriber #15	
	Prescriber #13	
	Prescriber #12	
	Prescriber #11 Prescriber #10	and the second
	Prescriber #10 Prescriber #9	
	Prescriber #8	-
	Prescriber #7	
	Prescriber #6	
	Prescriber #6 Prescriber #6	
	Prescriber #6 Prescriber #6 Prescriber #4	
	Prescriber #6 Prescriber #6	

RX Summary	Buprenorpi Last 30 D	hine (mg) Pres		er Time Last 90 Days Last 1 Year	Last 2 Years				ME) Prescribed Over Til ast 60 Days Last 90 1		st 1 Year Last	2 Years	
	List 30 D	ays Lasto	o bays	Last to Lays Last 1 fear	Last 2 Years			Last 30 Days	ast of Days Last of	Jays La			
	•• A	٨				26.4		9				LME	.59 Per Day Avg.
	g 34		$\wedge$	Δ <u>Λ</u>	1	20.1		No.					.51
	a	1	`		- m	Avg mg P		0		<u></u>		IME	mg Per Rx
	Disclaimer	211	DHI.	ty Timeframe	ay			Disclaimer		-9 Timeframe		ay	
	Morphine N	Ailligram Equiv	ralent Pres	cribed Over Time				RX Summary					
	Last 30 D			Last 90 Days Last 1 Year	Last 2 Years			Summary		(excluding Bupre		renorphine*	
	325					11.0	17	Total Prescriptions Total Private Pay	59 Current Q1 3 Current MI	WE/day	15.00 Curr	ent Qity ent mgiday	20 20.10
	붱 160				. Л	MME per D	lay Arg.	Total Prescribers Total Pharmacies	16 30 Day Av	g MME/day	11.07 30 D	ay Avg mgiday	26.42
	3.00	N	~ ^		N / N	27.3 MME pe	38						
	01/16/23	2m	0m	1y	ży	wwie pe	r KA						
	Disclaimer												
RX Summary	RX Summary	v Expanded											
		cluding Buprenorph	hine)	Buprenorphin	ie.			Sedatives		Stir	mulants		
Expanded	30 Day Avg. MM 90 Day Avg. MM			11.07 30 Day Avg. mgl 26.43 90 Day Avg. mgl			20.00 20.57	30 Day Avg. LME 90 Day Avg. LME			Day Avg. mg/day Day Avg. mg/day		0
•	Rx Count/12 Mor	nths		8 Rx Count/12 Mor	nths		13	Rx Count/12 Months		12 Rx 0	Count/12 Months		
	Prescriber #/6 M Pharmacy #/6 M			5 Prescriber #/6 M 7 Pharmacy #/6 M			2	Prescriber #/6 Months Pharmacy #/6 Months			scriber #/6 Months irmacy #/6 Months		
	Current Quantity	r		0 Current Quantity			90	Current Quantity		6 Cun	rent Quantity		
Prescriptions	Prescriptions Total: 61   Priv									Showing	1-15 of 61 items Vie	ar 15 litems <	1 of 5
	Filled +	Written ¢	ID ¢	Drug ¢	QTY \$	Days o	Prescriber		Dispensor o	Refill o	Daily Dose" o	Pymt Type ©	PMP
	01/12/2023	11/10/2022	6	Suboxone 6 Mg-2 MG SL Film	75	30	Prescriber 1	3154663	Pharm 1	0	20.00 MG	Comm Ins	IN
	01/11/2023	11/10/2022 11/10/2022	6	Suboxone 8 Mg-2 MG SL Film Cionazepam 0.25 MG Odt	15	5	Prescriber 1 Prescriber 1	3154683 3153834	Pharm 1 Pharm 11	0	24.00 MG 0.50 LME	Comm Ins	IN IN
	12/28/2022	12/28/2022	2	Hydrocodone-Acetamin 5-325 MG	6	2	Prescriber 1	0700820	Pharm 4	0	15.00 MME	Medicare	IN
	12/21/2022	12/21/2022	6	Hydrocodone-Acelamin 5-325 MG	10	7	Prescriber 1	1274701	Pharm 1	0	7.14 MME	Comm Ins	IN
	12/16/2022	12/12/2022	2	Suboxone 8 Mg-2 MG SL Film	60	30	Prescriber 1	3136764	Pharm 7	0	16.00 MG	Comm Ins	IN
	12/14/2022	11/10/2022	2	Clonazepam 0.25 MG Odt Suboxone 8 Mg-2 MG SL Film	30	30	Prescriber 1 Prescriber 1	3136749 3136754	Pharm 1 Pharm 1	0	0.50 LME	Comm Ins	IN
	12/07/2022	12/12/2022	5	Oxycodone Hol 10 MG Tablet	28	7	Prescriber 1	2105960	Pharm 8	0	60.00 MME	Comm Ins	IN
	11/17/2022	11/10/2022	2	Suboxone 8 Mg-2 MG SL Film	60	30	Prescriber 1	3120567	Pharm 1	0	16.00 MG	Medicare	IN
	11/17/2022	11/10/2022	2	Cionazepam 0.25 MG Odt	30	30	Prescriber 1	3120566	Pharm 1	0	0.50 LME	Medicare	IN
	10/20/2022	10/19/2022	2	Suboxone 8 Mg-2 MG SL Film	75	30	Prescriber 3	1259713	Pharm 16	0	20.00 MG	Medicare	IN
	10/19/2022	06/15/2022	2	Cionazepam 0.25 MG Odt Suboxone 8 Mg-2 MG SL Film	30	30	Prescriber 1 Prescriber 2	1259352	Pharm 1	0	0.50 LME	Medicare	IN
	09/25/2022	09/22/2022	2	Suboxone 6 Mg-2 MG SL Film	90	30	Prescriber 1	0347275	Pharm 2	0	24.00 MG	Comm Ins	IN
	Disclaimer									Showing	a 1-15 of 61 literms Vi	w 15 liems v	1 of 5
Providers	Providers												
Providers	Total: 17										ng 1-15 of 17 Items V		1 of 2
Providers	Total: 17 Name +				Address ‡			City ¢	State ¢	Z	Spcode s	Phone ‡	1 of 2
Providers	Total: 17				Address ‡ Provider Address 1 Provider Address 2			Springfield	IN	2		Phone \$	1 of 2
Providers	Total: 17 Name ‡ Prescriber 1				Provider Address 1					2	Dipcode ș	Phone ‡	() 1 of 2 (
Providers	Total: 17 Name 0 Pressiter 1 Pressiter 2 Pressiter 3 Pressiter 4				Provider Address 1 Provider Address 2 Provider Address 3 Provider Address 4			Springfield Springfield Springfield Springfield	IN IN IN IN	2	Elpcode 0 10399 10376 10178 10329	Phone ¢ Phone 1 Phone 2 Phone 3 Phone 4	1 d2
Providers	Total: 17 Name © Pescaber 1 Prescaber 2 Prescaber 3 Prescaber 4 Prescaber 5				Provider Address 1 Provider Address 2 Provider Address 3 Provider Address 4 Provider Address 5			Springfield Springfield Springfield Springfield Springfield	IN IN IN	2	5ipcode ¢ k0399 k0376 k0170	Phone ¢ Phone 1 Phone 2 Phone 3 Phone 4 Phone 5	1 of 2
Providers	Total: 17 Name 0 Pressiter 1 Pressiter 2 Pressiter 3 Pressiter 4				Provider Address 1 Provider Address 2 Provider Address 3 Provider Address 4			Springfield Springfield Springfield Springfield	IN IN IN IN	2	2ipcode: 0 103599 10378 10170 10379 10672	Phone ¢ Phone 1 Phone 2 Phone 3 Phone 4	1 of 2
Providers	Total: 17 Name: # Presabler 1 Presabler 2 Presabler 3 Presabler 4 Presabler 5 Presabler 5 Presabler 6				Provider Address 1 Provider Address 2 Provider Address 3 Provider Address 4 Provider Address 5 Provider Address 6 Provider Address 7 Provider Address 6			Bpringfield Bpringfield Springfield Springfield Bpringfield Springfield Springfield Springfield	IN IN IN IN IN IN IN	2	20000 (2000) 20000 (2000) 200000000000000000000000000000000	Phone \$ Phone 1 Phone 2 Phone 3 Phone 4 Phone 4 Phone 5 Phone 6 Phone 7 Phone 8	1 of 2
roviders	Total: 17 Name: # Preculare: 1 Presulter: 2 Presulter: 2 Presulter: 5 Presulter: 6 Presulter: 6 Presulter: 7 Presulter: 7				Provider Address 1 Provider Address 2 Provider Address 3 Provider Address 5 Provider Address 6 Provider Address 7			Springfield Springfield Springfield Springfield Springfield Springfield Springfield Springfield	IN IN IN IN IN IN IN IN IN	2 4 4 4 4 4 4 4 4 4 4 4 4 4	200006 8 000000 00000 00000 00170 00000 00072 00007 00151 00007 22345 00007	Phone \$ Phone 1 Phone 2 Phone 2 Phone 3 Phone 4 Phone 4 Phone 5 Phone 6 Phone 7 Phone 6 Phone 7 Phone	1 of 2
roviders	Total: 17 Name: # Presabler 1 Presabler 2 Presabler 3 Presabler 4 Presabler 5 Presabler 5 Presabler 6				Provider Address 1 Provider Address 2 Provider Address 3 Provider Address 4 Provider Address 6 Provider Address 7 Provider Address 9 Provider Address 9			Bpringfield Bpringfield Springfield Springfield Bpringfield Springfield Springfield Springfield	IN IN IN IN IN IN IN	2	20000 (2000) 20000 (2000) 200000000000000000000000000000000	Phone \$ Phone 1 Phone 2 Phone 3 Phone 4 Phone 4 Phone 5 Phone 6 Phone 7 Phone 8	1 of 2
roviders	Total: 17 Name: # Precodare 1 Precodare 3 Precodare 3 Precodare 3 Precodare 3 Precodare 5 Precodare 6 Precodare 6 Precodare 10 Precodare 10				Provider Address 1 Provider Address 2 Provider Address 3 Provider Address 3 Provider Address 6 Provider Address 7 Provider Address 9 Provider Address 9 Provider Address 9			Springfield Springfield Springfield Springfield Springfield Springfield Springfield Springfield Springfield	N N N N N N N N N		20000 0 00000 00000 0 0000 00070 0 00070 00077 0 00072 00077 0 00072 22345 0 0007	Phone 9 Phone 9 Phone 3 Phone 3 Phone 4 Phone 4 Phone 6 Phone 6 Phone 6 Phone 6 Phone 10	1 of 2
roviders	Total: 17 Name: # Presaders 1 Presaders 2 Presaders 3 Presaders 4 Presaders 7 Presaders 7 Presaders 10 Presaders 10 Presaders 11 Presaders 12				Provider Address 1 Provider Address 2 Provider Address 3 Provider Address 4 Provider Address 6 Provider Address 7 Provider Address 10 Provider Address 10 Provider Address 10 Provider Address 11 Provider Address 12 Provider Address 13			Eprophet Eprophet Scredist Scredist Scredist Enrophet Scredist Scredist Scredist Scredist Scredist Scredist Scredist			2pocode a 200299 200299 200299 200299 20020 20020 2000 20000 20000 20000 2000000	Phone 9 Phone 9 Phone 2 Phone 3 Phone 4 Phone 6 Phone 6 Phone 6 Phone 9 Phone 10 Phone 11 Phone 13	1 of 2
roviders	Total: 17 Name: # Precodare 1 Precodare 3 Precodare 3 Precodare 3 Precodare 3 Precodare 5 Precodare 6 Precodare 6 Precodare 10 Precodare 10				Provider Address 1 Provider Address 2 Provider Address 3 Provider Address 4 Provider Address 4 Provider Address 6 Provider Address 7 Provider Address 7 Provider Address 7 Provider Address 10 Provider Address 11 Provider Address 12 Provider Address 12 Provider Address 14			Boroglad Deringdad Storoglad Storoglad Storoglad Storoglad Storoglad Storoglad Storoglad Storoglad Storoglad	N N N N N N N N N		280006 0 0076 0076 0077 0051 0051 0051 0053 0057 0051 0051 0051 0051 0051 0051 0051	Phone 9 Phone 9 Phone 3 Phone 3 Phone 4 Phone 4 Phone 6 Phone 6 Phone 6 Phone 6 Phone 10	142
Providers	Total: 17 Name 1 Presubles 1 Presubles 2 Presubles 2 Presubles 4 Presubles 5 Presubles 7 Presubles 7 Presubles 7 Presubles 19 Presubles 11 Presubles 12 Presubles 12				Provider Address 1 Provider Address 2 Provider Address 3 Provider Address 4 Provider Address 6 Provider Address 7 Provider Address 10 Provider Address 10 Provider Address 10 Provider Address 11 Provider Address 12 Provider Address 13			Epiraphal Boreglasi Doroglasi Sconglasi Ecologia Boreglasi Sconglasi Sconglasi Sconglasi Sconglasi Sconglasi Sconglasi Sconglasi Sconglasi			20006 2 3 4 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4 5	Phone 9 Phone 9 Phone 3 Phone 4 Phone 3 Phone 4 Phone 5 Phone 6 Phone 7 Phone 6 Phone 10 Phone 11 Phone 13 Phone 14	
	Total: 17 Name 1 Presubles 1 Presubles 2 Presubles 2 Presubles 4 Presubles 5 Presubles 7 Presubles 7 Presubles 7 Presubles 19 Presubles 11 Presubles 12 Presubles 12	5			Provider Address 1 Provider Address 2 Provider Address 3 Provider Address 4 Provider Address 4 Provider Address 6 Provider Address 7 Provider Address 7 Provider Address 7 Provider Address 10 Provider Address 11 Provider Address 12 Provider Address 12 Provider Address 14			Epiraphal Boreglasi Doroglasi Sconglasi Ecologia Boreglasi Sconglasi Sconglasi Sconglasi Sconglasi Sconglasi Sconglasi Sconglasi Sconglasi			20006 2 3 4 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4 5	Phone 9 Phone 1 Phone 3 Phone 3 Phone 4 Phone 5 Phone 6 Phone 6 Phone 10 Phone 11 Phone 13	
	Total: 17 Name 1 Presabler 1 Presabler 2 Presabler 3 Presabler 4 Presabler 6 Presabler 7 Presabler 1 Presabler 10 Presabler 13 Presabler 13	•			Provider Address 1 Provider Address 2 Provider Address 3 Provider Address 4 Provider Address 4 Provider Address 6 Provider Address 7 Provider Address 7 Provider Address 7 Provider Address 10 Provider Address 11 Provider Address 12 Provider Address 12 Provider Address 14			Epiraphal Boreglasi Doroglasi Sconglasi Ecologia Boreglasi Sconglasi Sconglasi Sconglasi Sconglasi Sconglasi Sconglasi Sconglasi Sconglasi		2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	Abender e	Phone 9 Phone 1 Phone 3 Phone 3 Phone 4 Phone 5 Phone 6 Phone 6 Phone 10 Phone 11 Phone 13	1072
	Total: 17 Name: 1 Pecuation: 1 Pecuation: 2 Pecuation: 2 Pecuation: 2 Pecuation: 2 Pecuation: 4	9			Provider Address 1 Provider Address 2 Provider Address 3 Provider Address 3 Provider Address 5 Provider Address 5 Provider Address 6 Provider Addr			Buringladi Buringladi Scongladi Scongladi Buringladi Scongladi Scongladi Scongladi Scongladi Scongladi Scongladi Scongladi Scongladi		2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	Approvalue ::         Image: Construction of the const	Proce 1 Proce 1 Prove 2 Prove 3 Proce 4 Proce 4 Proce 6 Proce 6 Proce 10 Proce 11 Proce 11 Proce 11 Proce 11 Proce 13 Proce 13 Proce 14 Proce 10 Proce 10 Pr	1072
	Total: 17 Name: 4 Presuble: 1 Presuble: 2 Presuble: 1 Presuble: 1				Provider Address 1 Provider Address 2 Provider Address 3 Provider Address 4 Provider Address 5 Provider Address 5 Provider Address 6 Provider Address 7 Provider Address 6 Provider Addr			Buringlield Buringlield		2 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	Absolde         2	Proce 1 Prove 2 Prove 3 Prove 3 Prove 4 Prove 4 Prove 5 Prove 6 Prove 6 Prove 10 Prove 10 Pro	1 of 2
	Total: 17 Name: 1 Precuber 1 Precuber 2 Precuber 3 Presetter 4 Presetter 5 Presetter 7 Presetter 7 Presetter 7 Presetter 10 Presetter 10 Presetter 11 Presetter 13 Presetter 13 Presetter 13 Presetter 13 Presetter 13 Presetter 14 Presetter 13 Presetter 13 Presete	8			Provider Address 1 Provider Address 2 Provider Address 2 Provider Address 5 Provider Address 5 Provider Address 5 Provider Address 7 Provider Addr			Buringladi Buringladi Scongladi Scongladi Buringladi Scongladi Scongladi Scongladi Scongladi Scongladi Scongladi Scongladi Scongladi		Z 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 50eet 2 50eet 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	Tabender at	Proce 1 Prove 2 Prove 3 Prove 3 Prove 4 Prove 4 Prove 5 Prove 6 Prove 6 Prove 10 Prove 10 Pro	1072
	Total: 17 Name: 4 Presuble: 1 Presuble: 2 Presuble: 1 Presuble: 1	9			Provider Address 1 Provider Address 2 Provider Address 3 Provider Address 4 Provider Address 5 Provider Address 5 Provider Address 6 Provider Address 7 Provider Address 6 Provider Addr			Epiraplaki Baraglaki Songhaki Caraglaki Songhaki Songhaki Songhaki Songhaki Songhaki Songhaki Songhaki Songhaki Songhaki Songhaki Songhaki	IN IN IN IN IN IN IN IN IN IN IN IN IN I	2 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	Absolde         2	Proce 1 Prove 2 Prove 3 Prove 3 Prove 4 Prove 4 Prove 5 Prove 6 Prove 6 Prove 10 Prove 10 Pro	1072
	Total: 17 Name: 4 Prevable: 1 Prevable: 2 Prevable: 3 Prevable: 4 Prevable: 4 Prevable: 5 Prevable: 6 Prevable: 6 Prevable: 10 Prevable: 10 Prevable: 10 Prevable: 11 Prevable: 12 Prevable: 13 Prevable: 13 Prevable: 14 Prevable: 14 Prevable: 14 Prevable: 14 Prevable: 14 Prevable: 14 Prevable: 15 Prevable: 15 Prev	5			Pasadar Adareas 1 Pasadar Adareas 2 Pasadar Adareas 2 Pasadar Adareas 4 Pasadar Adareas 4 Pasadar Adareas 6 Pasadar Adareas 7 Pasadar Pasadar Adareas 7 Pasadar Pasada			Epiraplaki	IN IN IN IN IN IN IN IN IN IN IN IN IN I	2 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	Abender e         I           Abender	Proce 1 Prove 2 Prove 3 Prove 3 Prove 4 Prove 4 Prove 5 Prove 6 Prove 6 Prove 10 Prove 10 Pro	< 1 <i>d</i> 2
	Totol: 17 Name: 1 Pecuation: 1 Pecuation: 2 Pecuation: 2 Pecuation: 4 Pecuation: 4 Pecuation: 4 Pecuation: 4 Pecuation: 6 Pecuation: 10 Pecuation: 10 Pecuation	•			Provider Address 1 Provider Address 2 Provider Address 2 Provider Address 5 Provider Address 5 Provider Address 5 Provider Address 6 Provider Address 7 Provider Addr			Epiraphal Bornglada Dornglada Sornglada Bornglada Bornglada Sornglada	N N N N N N N N N N N N N N N N N N N	2 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	Approvalue         a           Approvalue         a <td>Proce 1 Prove 2 Prove 3 Prove 3 Prove 4 Prove 4 Prove 5 Prove 6 Prove 6 Prove 10 Prove 10 Pro</td> <td>1072</td>	Proce 1 Prove 2 Prove 3 Prove 3 Prove 4 Prove 4 Prove 5 Prove 6 Prove 6 Prove 10 Prove 10 Pro	1072
	Total: 17 Name: 4 Pecuation: 1 Pecuation: 2 Pecuation: 3 Pecuation: 4 Pecuation: 4 Pecuation: 4 Pecuation: 4 Pecuation: 9 Pecuation: 9 Pecuation: 9 Pecuation: 9 Pecuation: 9 Pecuation: 10 Pecuation: 10	•			Pasadar Adareas 1 Pasadar Adareas 2 Pasadar Adareas 2 Pasadar Adareas 4 Pasadar Adareas 4 Pasadar Adareas 6 Pasadar Adareas 7 Pasadar Pasadar Adareas 7 Pasadar Pasada			Epiraphal Epiraphal Epiraphal Scoregisal Epiraphal Epiraphal Epiraphal Scoregisal Epiraphal Epiraphal Epiraphal Epiraphal Epiraphal Scoregisal Epiraphal Epiraphal Epiraphal Epiraphal Epiraphal Epiraphal Epiraphal Epiraphal Epiraphal Epiraphal Epiraphal Epiraphal Epiraphal Epiraphal	IN IN IN IN IN IN IN IN IN IN IN IN IN I	2 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	Abender e         I           Abender	Proce 1 Prove 2 Prove 3 Prove 3 Prove 4 Prove 4 Prove 5 Prove 6 Prove 6 Prove 10 Prove 10 Pro	< 1 <i>d</i> 2
	Totol: 17 Name: 1 Pecuation: 1 Pecuation: 2 Pecuation: 2 Pecuation: 4 Pecuation: 4 Pecuation: 4 Pecuation: 4 Pecuation: 6 Pecuation: 10 Pecuation: 10 Pecuation	•			Pouder Adams 1 Pouder Adams 2 Pouder Adams 2 Pouder Adams 3 Pouder Adams 5 Pouder Adams 5 Pouder Adams 5 Pouder Adams 7 Pouder			Epiraphal Bornglada Dornglada Sornglada Bornglada Bornglada Sornglada	N           N	2 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	Absolde         a           Absolde	Proce 1 Prove 1 Prove 2 Prove 3 Prove 3 Prove 4 Prove 5 Prove 6 Prove 10 Prove 10 Pr	< 1 <i>d</i> 2
	Total: 17 Mase: 2 Pecable: 2 Pecable: 2 Pecable: 3 Pecable: 4 Pecable: 4 Pecable: 3 Pecable: 10 Pecable: 10 Peca				Pouder Adams 1 Pouder Adams 2 Pouder Adams 2 Pouder Adams 3 Pouder Adams 5 Pouder Adams 5 Pouder Adams 5 Pouder Adams 7 Pouder			Episqlad Episqlad Episqlad Songlad Episqlad Episqlad Episqlad Songlad Episqlad Episqlad Episqlad Episqlad Episqlad Songlad Episqlad Episqlad Episqlad Episqlad Episqlad Episqlad Episqlad Episqlad	N           N	2 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	Absold         a           Absold         a <td>Proce 1 Prove 1 Prove 2 Prove 3 Prove 3 Prove 4 Prove 5 Prove 6 Prove 10 Prove 10 Pr</td> <td>&lt; 1<i>d</i>2</td>	Proce 1 Prove 1 Prove 2 Prove 3 Prove 3 Prove 4 Prove 5 Prove 6 Prove 10 Prove 10 Pr	< 1 <i>d</i> 2
	Totol: 17 Name: 4 Pecuation: 1 Pecuation: 2 Pecuation: 3 Pecuation: 4 Pecuation:	8			Paudar Adaress 1 Paudar Adaress 2 Paudar Adaress 2 Paudar Adaress 3 Paudar Adaress 4 Paudar			Epiraplad Epirap	N           N	2 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	Tabende e         1         1           2020         1         1<	Proce 1 Prove 1 Prove 2 Prove 3 Prove 3 Prove 4 Prove 5 Prove 6 Prove 10 Prove 10 Pr	< 1 <i>d</i> 2
	Total: 17 Mase: 2 Pecable: 2 Pecable: 2 Pecable: 3 Pecable: 4 Pecable: 4 Pecable: 3 Pecable: 10 Pecable: 10 Peca	9			Pouder Adams 1 Pouder Adams 2 Pouder Adams 2 Pouder Adams 3 Pouder Adams 5 Pouder Adams 5 Pouder Adams 5 Pouder Adams 7 Pouder			Episqlad Episqlad Episqlad Songlad Episqlad Episqlad Episqlad Songlad Episqlad Episqlad Episqlad Episqlad Episqlad Songlad Episqlad Episqlad Episqlad Episqlad Episqlad Episqlad Episqlad Episqlad	N           N	2 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	Absold         a           Absold         a <td>Proce 1 Prove 1 Prove 2 Prove 3 Prove 3 Prove 4 Prove 5 Prove 6 Prove 10 Prove 10 Pr</td> <td>0 142 (</td>	Proce 1 Prove 1 Prove 2 Prove 3 Prove 3 Prove 4 Prove 5 Prove 6 Prove 10 Prove 10 Pr	0 142 (
Providers	Totol: 17 Name: 1 Pecuation: 1 Pecuation: 2 Pecuation: 2 Pecuation: 3 Pecuation: 4 Pecuation: 4 Pecuation: 4 Pecuation: 4 Pecuation: 10 Pecuation: 10 Perumane: 1	<b>a</b>			Paudar Adams 1 Paudar Adams 2 Paudar Adams 2 Paudar Adams 3 Paudar Adams 5 Paudar Adams 5 Paudar Adams 5 Paudar Adams 6 Paudar Adams 6 Paudar Adams 7 Paudar			Episophal Episop		2 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	Approvable         a         b           Approvable         a         c	Proce 1 Prove 1 Prove 2 Prove 3 Prove 3 Prove 4 Prove 5 Prove 6 Prove 10 Prove 10 Pr	

**Note:** The tiles displayed to you may vary from the above layout depending on the configurations established by your PDMP administrator. For example, the PDMP administrator may request additional tiles for display in the interface for their PDMP that are not displayed in the above layout.

An overview of each tile can be found in the NarxCare Overview section of this document.

**CAUTION/IMPORTANT REMINDER:** NarxCare is intended to aid, not replace, medical decision-making. None of the information presented should be used as sole justification for providing or refusing to provide medications.

# NarxCare Overview

NarxCare was designed to provide an intuitive view of dispensing information for a patient. This information is presented as tiles, many of which are interactive, allowing the user to click or hover over links and graphs within a tile to access additional information.

**Note:** The list of tiles described below is not comprehensive. This is a list of the most commonly activated tiles by PDMP administrators. You may not see all of the tiles described below and you may see additional tiles in your layout that are not described below. The tiles displayed to you are configured by your PDMP administrator.

# Header and Patient Identifying Information

The NarxCare header contains patient identifying information in the first line above the tiles. Additional patient information, such as date of birth and address, can be found directly below the header. This information will remain visible at the top of your screen as you scroll through the various tiles.

LFIFST Na Date of Birth:	me] [Last Name], [Age] [ Recent Address:	Status of States Queried:	Contact the Bamboo Health Knowledge/Help
[00/00/0000]	[Street Name, County, State, Zip Code]	Error for 1 or more states View Details View Linked Records (1) V	Other Tools/Metric
NarxCar	e®		
NarxCar	e~		

You can click View Linked Records to display all records linked to the selected patient.

eport Criteria	Linked Record	ls <sup>⊕</sup>			
st Name: [First Name] st Name: [Last Name] B: [00/00/0000]	Name [First Name] [Last Nar [First Name] [Last Nar [First Name] [Last Nar [First Name] [Last Nar [First Name] [Last Nar	me] [00/00/0000] me] [00/00/0000] me] [00/00/0000] me] [00/00/0000]	ID         Gender           1         [Gender]           2         [Gender]           3         [Gender]           4         [Gender]           5         [Gender]           6         [Gender]	tess et Namo, County, State, Zp Codej et Namo, County, State, Zp Codej	
Narx Scores Narcotic	/16/2023. Report Date Ran Sedative Stimulant 541 000 Explanation and Quidanc	Overdos	e Risk Score 7300 (Range 000-995	State Indicators (3)       ■ > 4 opoid or reduite dispensing pharmacies in any 90 day period in the last 2 years       ■ > 5 opoid or reduite provides in any year in the last 2 years       • >100 MME total and 40 MME/day average       on and Outdance	🙆 PDF Report 🛛 Expo
				Detais	

# Prescription Detail

Each prescription dispensed to a patient is presented in the **Prescriptions** tile. If desired, you can use the arrows next to each column header (\$) to sort the table by that column. You can also hover your cursor over a prescriber or pharmacy to view additional information, such as the prescriber or pharmacy's full name, address, and DEA number.

Total: 61   F	Private Pay: 3								Showing 1-1	IS of 61 Items View	15 Items <	1 of 5 🤇
Filled 🗸	Written o	ID ¢	Drug ¢	QTY 0	Days ¢	Prescriber (	RX# 0	Dispenser §	Refill ¢	Daily Dose' (	Pymt Type 🗄	PMP (
01/12/2023	11/10/2022	6	Suboxone 8 Mg-2 MG SL Film	75	30	Prescriber 1	3154683	Pharm 1	0	20.00 MG	Comm Ins	IN
01/11/2023	11/10/2022	6	Suboxone 8 Mg-2 MG SL Film	15	5	Prescriber 1	3154683	Pharm 1	0	24.00 MG	Comm Ins	IN
01/10/2023	11/10/2022	6	Cionazepam 0.25 MG Odt	30	30	Prescriber 1	3153834	Pharm 11	0	0.50 LME	Comm Ins	IN
12/28/2022	12/28/2022	2	Hydrocodone-Acetamin 5-325 MG	6	2	Prescriber 1	0700920	Pharm 4	0	15.00 MME	Medicare	IN
12/21/2022	12/21/2022	6	Hydrocodone-Acetamin 5-325 MG	10	7	Prescriber 1	1274701	Pharm 1	0	7.14 MME	Comm Ins	IN
12/16/2022	12/12/2022	2	Suboxone 8 Mg-2 MG SL Film	60	30	Prescriber 1	3136764	Pharm 7	0	16.00 MG	Comm Ins	IN
12/14/2022	11/10/2022	2	Clonazepam 0.25 MG Odt	30	30	Prescriber 1	3136749	Pharm 1	0	0.50 LME	Comm Ins	IN
12/14/2022	12/12/2022	2	Suboxone 8 Mg-2 MG SL Film	30	10	Prescriber 1	3136754	Pharm 1	0	24.00 MG	Comm Ins	IN
12/07/2022	12/07/2022	5	Oxycodone Hcl 10 MG Tablet	28	7	Prescriber 1	2105980	Pharm 8	0	60.00 MME	Comm Ins	IN
11/17/2022	11/10/2022	2	Suboxone 8 Mg-2 MG SL Film	60	30	Prescriber 1	3120667	Pharm 1	0	16.00 MG	Medicare	IN
11/17/2022	11/10/2022	2	Clonazepam 0.25 MG Odt	30	30	Prescriber 1	3120666	Pharm 1	0	0.50 LME	Medicare	IN
10/20/2022	10/19/2022	2	Suboxone 8 Mg-2 MG SL Film	75	30	Prescriber 3	1259713	Pharm 16	0	20.00 MG	Medicare	IN
10/19/2022	06/15/2022	2	Cionazepam 0.25 MG Odt	30	30	Prescriber 1	1259352	Pharm 1	0	0.50 LME	Medicare	IN
10/19/2022	10/19/2022	2	Suboxone 8 Mg-2 MG SL Film	15	5	Prescriber 2	1259713	Pharm 1	0	24.00 MG	Medicare	IN
09/25/2022	09/22/2022	2	Subcone 8 Mg-2 MG SL Film	90	30	Prescriber 1	0347275	Pharm 2	0	24.00 MG	Comm Ins	IN

## Provider and Pharmacy Detail

Provider and pharmacy information, including full name, address, and DEA number (if applicable), is presented in the **Providers** and **Pharmacies** tiles.

Total: 17					
ame \$	Address ¢	City \$	State ¢	Zipcode \$	Phone \$
rescriber 1	Provider Address 1	Springfield	IN	40399	Phone 1
rescriber 2	Provider Address 2	Springfield	IN	40376	Phone 2
escriber 3	Provider Address 3	Springfield	IN	40178	Phone 3
ascriber 4	Provider Address 4	Springfield	IN	40329	Phone 4
iscriber 5	Provider Address 5	Springfield	IN	40672	Phone 5
scriber 6	Provider Address 6	Springfield	IN	40907	Phone 6
scriber 7	Provider Address 7	Springfield	IN	40151	Phone 7
scriber 8	Provider Address 8	Springfield	IN	42345	Phone 8
scriber 9	Provider Address 9	Springfield	IN	44533	Phone 9
scriber 10	Provider Address 10	Springfield	IN	44533	Phone 10
scriber 11	Provider Address 11	Springfield	N	40907	Phone 11
scriber 12	Provider Address 12	Springfield	IN	40376	Phone 12
scriber 13	Provider Address 13	Springfield	IN	44533	Phone 13
scriber 14	Provider Address 14	Springfield	IN	40907	Phone 14
scriber 15	Provider Address 15	Springfield	IN	40376	Phone 15
				Showing 1-15 of 17 Items Vie	w 15 liems v 1 of 2
fotal: 17	Address ;	City :	State ÷		
Fotal: 17 me ¢	Address : Plantacy Address 1	City ÷ Springheal	State ÷ N	Showing 1-15 of 17 litems Vie	w 15 ltems v 🔇 1 of 2
otal: 17 me : armacy 1				Showing 1-15 of 17 flams Vie Zipcode ¢	w 15 ltems v 🔇 1 of 2
fotal: 17 me : armacy 1 armacy 2	Pharmacy Address 1	Springfield	IN	Showing 1-15 of 17 Items Vie Zipcode ‡ 40329	w 15 ltems v 🔇 1 of 2
fotal: 17 me : armacy 1 armacy 2 armacy 3	Pharmacy Address 1 Pharmacy Address 2	Springfield	N N	Showing 1-15 of 17 Items Vie Zipcode \$ 40329 40672	w 15 ltems v 🔇 1 of 2
lotat: 17 mme ‡ armacy 1 armacy 2 armacy 3 armacy 4	Pharmacy Address 1 Pharmacy Address 2 Pharmacy Address 3	Springfield Springfield Springfield	N N N	Showing 1-15 of 17 Items Vie Zipcode 9 40029 40672 40007	w 15 ltems v 🔇 1 of 2
Totat: 17 amar; 1 amar; 2 amar; 2 amar; 3 amar; 4 amar; 5	Pharmacy Address 1 Pharmacy Address 2 Pharmacy Address 3 Pharmacy Address 4	Springfield Springfield Springfield Springfield	IN IN IN	Showing 1-16 of 17 Timens Vie Zapcode : 40329 4 40572 4 4057 40515 1	w 15 ltems v 🔇 1 of 2
Total: 17 armacy 1 armacy 2 armacy 3 armacy 4 armacy 6	Parriary Addinis 1 Planniny Addinis 2 Planniny Addinis 3 Planning Addinis 4 Planning Addinis 5	Springfield Springfield Springfield Springfield Springfield	N N N N	Showing 1-15 of 17 Items Vie Zepcode ± 40309 40972 40907 4051 42345	w 15 ltems v 🔇 1 of 2
lotat: 17 armaç 1 armaç 2 armaç 2 armaç 4 armaç 6 armaç 6 armaç 7	Pearsacy Address 1 Pearsacy Address 2 Pearsacy Address 4 Pearsacy Address 5 Pearsacy Address 5 Pearsacy Address 5	Spingheid Spingheid Spingheid Spingheid Spingheid Spingheid	IN IN IN IN IN IN	Bhowing 1-15 of 17 ferms         Vite           Zipicoder g         40229           40272         40672           4057         40551           40551         44333	w 15 ltems v 🔇 1 of 2
Iotal: 17 me 1 mmary 1 mmary 2 mmary 2 mmary 4 mmary 6 mmary 6 mmary 6 mmary 6 mmary 7 mmary 8	Pearsacy Address 1 Pearsacy Address 1 Pearsacy Address 2 Pearsacy Address 3 Pearsacy Address 4 Pearsacy Address 6 Pearsacy Address 6 Pearsacy Address 7	Spinghes Spinghes Spinghes Spinghes Spinghes Spinghes Spinghes Spinghes	IN IN IN IN IN IN IN IN	Otherway 1-15 of 17 Items         Yet           Zepcode ±         40579           40579         40977           40977         40951           42554         44533	w 15 ltems v 🔇 1 of 2
fotat: 17 mm s s amacy 1 amacy 2 amacy 2 amacy 3 amacy 5 amacy 6 amacy 6 amacy 7 amacy 8 amacy 9	Pearsacy Address 1 Pearsacy Address 2 Pearsacy Address 3 Pearsacy Address 3 Pearsacy Address 4 Pearsacy Address 4 Pearsacy Address 7 Pearsacy Address 5 Pearsacy Address 5	Springheid Springheid Springheid Springheid Springheid Springheid Springheid	8) 8) 8) 8) 8) 8) 8) 8) 8) 8)	Blowing 1-15 of 17 hums         Yris           Zgocole ±         40309           40309         40072           40077         40151           42345         44333           44333         44333           44376         40376	w 15 ltems v 🔇 1 of 2
Total: 17 armacy 1 armacy 2 armacy 2 armacy 4 armacy 4 armacy 6 armacy 6 armacy 6 armacy 7 armacy 10 armacy 10	Partnacy Address 1 Plantnacy Address 2 Plantnacy Address 2 Plantnacy Address 4 Plantnacy Address 4 Plantnacy Address 5 Plantnacy Address 6 Plantnacy Address 6 Plantnacy Address 7 Plantnacy Address 9 Plantnacy Plantnacy Address 9 Plantnacy Plantnacy Address 9 Plantnacy Plantna	Senangheid Schamphold Schamphold Schamphold Schamphold Schamphold Schamphold Schamphold	N N N N N S N N N	Zipcode ‡         Vit           2020         ‡           40309         ‡           40509         ‡           40517         4067           40517         4051           40537         4053           40537         4053           4053         4053	w 15 ltems v 🔇 1 of 2
Pharmacles Total: 17 Total: 17 amrato 1 amrato 2 amrato 2 amrato 2 amrato 4 amrato 4 amrato 4 amrato 4 amrato 9 amrato 9 a amrato 9 a amrato 9 a amrato 9 a amrato 9 a a a a a a a a a	Paranacy Address 1 Paranacy Address 2 Paranacy Address 3 Paranacy Address 4 Paranacy Address 4 Paranacy Address 6 Paranacy Address 7 Paranacy Address 7 Paranacy Address 8 Paranacy Address 8 Paranacy Address 10	Sponghed Sponghed Sponghed Sponghed Sponghed Sponghed Sponghed Sponghed Sponghed Sponghed	79 79 79 79 70 70 70 70 70 70 70 70	Ottowing 1-15 of 17 Items         Yes           Zigcode ‡            40305            4097            4097            4097            44351            44353            44333	w 15 Items ~ < 1 of 2
Total: 17 ama: 1 amacy 1 amacy 2 amacy 2 amacy 2 amacy 3 amacy 6 amacy 6 amacy 7 amacy 7 amacy 1 amacy 10 amacy 12	Particy Address 1 Particy Address 1 Particy Address 2 Particy Address 3 Particy Address 4 Particy Address 4 Particy Address 6 Particy Address 7 Particy Address 9 Particy Address 9 Particy Address 19 Particy Address 11 Particip Address 11 Particip Pa	Spingheid Spingheid Spingheid Spingheid Spingheid Spingheid Spingheid Spingheid Spingheid	19 95 96 98 98 98 98 98 98 98 98 98 98 98	Streaming 1-15 of 17 herms         Yes           Zgroode ;         40309           40309         40572           40572         40577           40515         40333           44333         44333           440376         40376           440376         40376	w 15 ltems v 🔇 1 of 2
Total: 17 imme 1 immey 1 immey 2 immey 2 immey 3 immey 4 immey 6 immey 6 immey 6 immey 9 immey 9 immey 10 immey 11 immey	Partnary Address 1 Partnary Address 2 Partnary Address 2 Partnary Address 4 Partnary Address 5 Partnary Address 6 Partnary Address 7 Partnary Address 7 Partnary Address 8 Partnary Address 8 Partnary Address 9 Partnary Address 1 Partnary Address 11 Partnary Address 12 Partnary Address 1	Spinghei Spinghei Spinghei Spinghei Spinghei Spinghei Spinghei Spinghei Spinghei	N N N N N N N N	2Booking 1-15 of 17 huma         Yis           2gcoole 1         40309           40309         4057           4007         40151           42345         44333           440376         40077           440376         44533           44533         46376           44533         46376           44533         46376	w 15 Items ~ < 1 of 2

## Rx Graph

The **Rx Graph** tile displays prescribing information and allows you to see important patterns and levels of use. The **Rx Graph** displays information in reverse chronological order; meaning the most recent prescriptions are displayed on the left side of the graph and the oldest are displayed on the right.

RX Graph								
Narcotic 🛃 Bup	renorphine 🔽 Seda	tive Stimulant	Other					① Learn how to use graph
All Prescribers								
Prescribers								
Prescriber #16								
Prescriber #15								1.1
Prescriber #14								
Prescriber #13								
Prescriber #12								
Prescriber #11					 _			
Prescriber #10								
Prescriber #9								
Prescriber #8								
Prescriber #7								
Prescriber #6								
Prescriber #5							_	
Prescriber #4								
Prescriber #3								
Prescriber #2		E .				1000		
Prescriber #1								
limeline	01/16	2m	6m	 1y				2y

Prescriptions are color coded and can be selected or deselected at the top of the graph. Color coding is as follows:

- Narcotics (opioids) = red
- Buprenorphines = **purple**
- Sedatives (benzodiazepines, sleep aids, etc.) = blue
- Stimulants = green
- Other = grey\*

\*Note: Other prescriptions can include anesthetics, cannabinoids, GI narcotics, steroids, and medications used to treat neuropain (e.g., gabapentin).

Each pixel in the graph represents one day. Therefore, a 30-day prescription is represented by a rectangle about 1 cm wide and a 1–3-day prescription appears as a narrow vertical bar.



The **Rx Graph** is interactive. You can click on a prescription to view information for that prescription, or you can click and drag over multiple prescriptions to view information for the selected prescriptions.

Narcotic V Bupre	norphine 🗾 Sedat	ive 🔽 Stimula	ant 🗹 Other										Dearn how to use graded to be a set of the set of th
II Prescribera											1		10.00
rescribers													
rescriber #16													
escriber #15													1.1
escriber #14	2											×	
escriber #13			Drug Details									~	
encriber #12	1		Fill Date	Drug	Qty	Days	Prescriber	Pharm	Refil	MgEq	MgEq/Day		
escriber #11			12/07/2022	Oxycodone Hol 10 MG Tablet	28.00		Prescriber 2	Pharm 1		1012.50	33.75		-
escriber #10			11/17/2022	Subaxone 8 Mg-2 MG SL Film		30	Prescriber 2	Pharm 1		60.30			
escriber #9			11/17/2022	Cionazepam 0.25 MG Odt	30.00		Prescriber 2	Pharm 1		1012.60	33.75		
escriber #8			10/20/2022	Subaxone 8 Mg-2 MG SL Film	75.00	15	Prescriber 2	Pharm 1	1	60.30			
escriber #7			10/19/2022	Clonazepam 0.25 MG Oct	30.00	30	Prescriber 1	Pharm 1	0	1012.50	33.75		
escriber #6			10/19/2022	Suboxone 8 Mg-2 MG SL Film	15.00	5	Prescriber 1	Pharm 1	0	60.30		1 1	
escriber #5													
escriber #4													
escriber #3													
rescriber #2												100	
resorber #1													

# Other graphs

If configured by your PDMP administrator, the **Rx Summary and Rx Summary Expanded** tiles may also be included in your NarxCare interface. The **Rx Summary** tile includes:

#### • Morphine Milligram Equivalent Prescribed Over Time



#### • Buprenorphine (mg) Prescribed Over Time



#### • Lorazepam MgEq (LME) Prescribed Over Time



These tiles contain graphs that provide a longitudinal view of daily MME, buprenorphine, and LME.

*Note:* Abrupt changes in trends may be due to overlapping prescriptions. Clinicians can review detailed information on the prescriptions in the *Prescriptions, Providers, and Pharmacies* tiles.

You can customize the length of time for which you wish to view information by clicking Last 30 Days (displayed by default), Last 60 Days, Last 90 Days, Last 1 Year, or Last 2 Years at the top of each graph.

*Note:* You can hover over the timeline in any of these graphs to display information for a specific day.

11/10/2014: 2 mg	
2	
	2
	mg Per Day Av
2 1-	00
	60 Avg mg Per F

# **Download Options**

If you need to download a PDF or CSV version of the report, click the **Export** dropdown menu, then click **Download PDF** or **Download CSV**.

	Export ^
Showing 1-10 of 10 Items View 15 Items V	Download CSV Download PDF

# Other Tools/Metrics

To view **Other Tools/Metrics** available to you, click on the dropdown menu located on the top right-hand side of the page to display your additional options.

[First Name] [Last	Contact the Bamboo Health Knowledge/Heip Cent			
NarxCare® Report generated on 01/16	/2023. Report Date Range: 0	1/16/2021 - 01/16/2023		DPF Report 🗹 Export
Narx Scores Narcotic Sed 791 54	ative Stimulant 41 000	Overdose Risk Score 730 (Range 000-969)	State Indicators (3)       → 4 spiciol or vaciative dispensing pharmacies in samy 50 day period in the last 2 years:       → 5 spiciol or vaciative providers in any year in the last 2 years:       → >100 MME total and 40 MME/day average	
	Explanation and Guidance	Explanation and Guidance	Details	

### Resources

The **Resources** dropdown menu contains easy access links to *MOUD Providers* and *PDMP & CDC Resources* that may be useful to coordinate care or review CDC guidelines.

Image: Test Name]         Image: Test Name]         Image: Test Name]         Test Name] <thtest name]<="" th=""></thtest>					
NarxCare® Report generated on 01/16	/2023. Report Date Range: 0	1/16/2021 - 01/16/2023	D PDF Report Z Export	Other Health Information	
	tative Stimulant 41 000	Overdose Risk Score 730 (Range 000-999)	State Indicators (3) State Indicators dispersing phereacies in any 90 day period in the last 2 years State S displat or seddlive providers in any year in the last 2 years 1 -100 MME lotal and 40 MME/day everage	Ø Resources (2) ∧ MAT Providers State & CDC Resources	
	Explanation and Guidance	Explanation and Guidance	Details		

#### **MOUD** Providers

The **MOUD Providers** pop-up window allows users to locate the 30 closest providers who are listed in the *Substance Abuse and Mental Health Services Administration (SAMHSA)* buprenorphine treatment locator database.

MAT Providers	×
Find the 30 closest MAT providers for this patient. The patient's zip code is pre-populated if available. View more information about the treatment locator.	
Zip Code	
40212	
Submit	

The patient's zip code is pre-populated but can be edited. After entering the desired Zip Code, click **Submit** to generate a PDF that can be viewed and printed.

*Note:* These resources are provided by the Substance Abuse and Mental Health Services Administration (SAMHSA). View more information about the treatment locator <u>here</u>.

#### PDMP & CDC Resources

The **State & CDC Resources** pop-up window provides a series of PDMP & CDC documents pertaining to both providers and patients.

*Note:* Your PDMP may not have additional resources available under the *Resources* link as this is a supplemental feature. Please contact your PDMP administrator if you would like additional information on CDC resources.



To assist providers in educating their patients, printable pamphlets are also available from the CDC. In addition to CDC-provided resources, and in coordination with the *Bureau of Substance Addiction Services (BSAS)*, specific resources, as selected by the applicable PDMP administrator, are also available. More information about CDC resources can be found <u>here</u>.

# Indicators and Scores

The NarxCare application includes a series of indicators and scores that may be automatically returned to the requesting system as discrete data. The indicators displayed will either be **Additional Indicators** or **Additional State Indicators**. Additional Indicators are the default indicators returned. These are replaced by Additional <u>State</u> Indicators if Additional State Indicators are configured by the applicable PDMP administrator. The scores returned are **Narx Scores** and **Overdose Risk Scores**. Requesting systems receiving such data can choose to display it within the native electronic health record (EHR) or pharmacy management system. However, many systems choose to display the data within the NarxCare application as tiles.

For additional information on Narx Scores and Overdose Risk Scores, please refer to the <u>Narx</u> <u>Scores</u> and <u>Overdose Risk Scores</u> respective sections in this document.



# Additional Indicators

**Additional Indicators** will display automatically. This type of indicator is not configured by PDMP administrators. The **Additional Indicators** tile includes a set of three binary indicators formed from data aggregated from the PDMP.



There are currently three standard Additional Indicators:

- More than 5 controlled substance providers in any 365-day period
- More than 4 pharmacies that dispense controlled substances in any 90-day period
- More than 40 MME average over the previous 2 years and having total prescription(s) for more than 100 MME at any time during the previous 2 years

These indicators are based on the following literature:

- **Provider Indicator:** Hall AJ, Logan JE, Toblin RL, et al. Patterns of Abuse Among Unintentional Pharmaceutical Overdose Fatalities. *JAMA*. 2008;300(22): 2613–2620. doi:10.1001/jama.2008.802.
- **Pharmacy Indicator:** Yang Z, Wilsey B, Bohm M, et al. Defining Risk of Prescription Opioid Overdose: Pharmacy Shopping and Overlapping Prescriptions Among Long-Term Opioid Users in Medicaid. *The Journal of Pain.* 16(5): 445–453.
- **40 MME Indicator:** Paulozzi L, Kilbourne E, Shah N, et. al. A History of Being Prescribed Controlled Substances and Risk of Drug Overdose Death. *Pain Medicine.* 2012;13(1): 87–95. doi: 10.1111/j.1526-4637.2011.01260.x.

*CAUTION / IMPORTANT REMINDER:* Clinicians use standard PDMP-based Additional Indicators to further review details in the patient's prescription history while attending to their patients. Additional Indicators are intended to aid, not replace, medical decisionmaking. None of the information presented should be used as sole justification for providing or refusing to provide medications.

## Additional State Indicators

The **Additional State Indicators** feature delivers configurable indicators to clinicians to identify when patients meet or exceed PDMP-specified thresholds. These indicators are configured by PDMP administrators.

The list below outlines the most common configurable indicators PDMP administrators typically choose to enable for display in the NarxCare application under the **Additional State Indicators** section.

Additional State Indicator	Description
Prescriber & Dispenser Thresholds	Displays when the number of prescribers and dispensers specified by your PDMP Administrator is met or exceeded within a set time period.
Daily Active MME Threshold	Displays when the daily active morphine milligram equivalent (MME) is greater than or equal to the value specified by your PDMP Administrator.
Opioid & Benzodiazepine Threshold	Displays when opioids and benzodiazepines are prescribed within the time period set by your PDMP Administrator.
Daily Active Methadone Threshold	Displays when the daily active MME for methadone is greater than or equal to the value specified by your PDMP Administrator.
Opioid Consecutive Days Threshold	Displays when opioids have been received daily for longer than the time period set by your PDMP Administrator.

#### Note:

- The Additional State Indicators available to you, and the thresholds associated with them, are configured by your PDMP administrator. PDMPs can submit a request for additional indicator types (e.g., death data) that are felt to espouse high correlations with adverse patient outcomes and are relevant to their jurisdiction's population. These additional indicators do not impact Narx Scores or Overdose Risk Scores.
- If any of the configurable Additional State Indicators are not activated by your PDMP administrator, the standard PDMP-based Additional Indicators tile will display. For additional information on the standard Additional Indicators tile, please refer to the <u>Additional</u> <u>Indicators</u> section of this document.

You can view a detailed description of the **Additional State Indicators** displayed by clicking the **Details** link located at the bottom right-hand corner of the **Additional State Indicators** tile. Once you click this link, the **Additional Indicators** details modal is displayed as shown below.

Add	ditional Indicato	Print Print
An a	dditional risk indicator as	ssessment reveals the following concerns for
0	Exceeds Daily Active MME Threshold	Description           Please note that this person has received controlled substances prescriptions equal to or greater than 115 MME/D. This equals or exceeds the threshold of 45 MME/D.           Patient's Counts         Alert Thresholds           115         45           Alert Date: 8/23/2021
0	Exceeds Opioid & Berzodiazepine Threshold	Description Please note that this person has received controlled substances prescriptions for both an Opioid and a Benzodiazepine within the same time period. Below Daily Active Methadone Threshold Prescription Counts Opioid: 4 Benzodiazepine: 1 Alert Date: 8/23/2021
		Close

*Note:* If configured by your PDMP administrator, this modal may also display an *Explanation* section containing additional information, provided by the PDMP administrator, about why you are seeing this indicator.

**CAUTION / IMPORTANT REMINDER:** Clinicians use Additional State Indicators to further review details in the patient's prescription history while attending to their patients. Additional State Indicators are intended to aid, not replace, medical decision-making. None of the information presented should be used as sole justification for providing or refusing to provide medications.

# Narx Scores

The NarxCare application provides three substance-specific (i.e., Narcotics, Sedatives, Stimulants) exposure scores for prescribing and dispensing of controlled substances as it relates to a patient called Narx Scores.

#### How are Narx Scores Used?

Narx Scores are intended to be automatically delivered into the clinical workflow as discrete data and be easily viewable within a patient's record. Many systems choose to place Narx Scores in the patient header or alongside the patient's vital signs.

Narx Scores were designed to increase provider awareness of a patient's controlled substance exposure. Thus, in order for the provider to derive the greatest informational utility from the scores, we encourage their viewing early during the patient encounter.

*Note:* Workflows may vary by organization. Please contact your organization administrator for additional information.

#### Narx Score Calculations and Metrics

Each Narx Score has a numerical value based on a synthesis of key patient metrics derived from the PDMP.

Narx Scores are calculated for narcotics, sedatives, and stimulants and have the following characteristics:

- 1. Each score consists of three digits ranging from 000–999.
- 2. The first two digits represent a *relative scoring* system for a given patient's exposure to a controlled substance compared to the rest of the PDMP population (described in detail below).
- 3. The <u>last digit</u> of each score represents the number of active prescriptions of that type. For example, a Narcotic Narx Score of 50<u>4</u> indicates the patient has four active narcotic prescriptions according to information obtained from the PDMP on dispensations.
- 4. The scores correspond to the prevalence and timing of literature-based risk factors<sup>4</sup> that exist within the PDMP data for that specific patient.
  - There are four metrics used in Narx Score calculations. They are as follows:
    - The number of controlled substance prescribers visited.
    - The number of pharmacies visited where controlled substance prescriptions were filled.

<sup>&</sup>lt;sup>4</sup> Hall AJ, Logan JE, Toblin RL, et al. Patterns of Abuse Among Unintentional Pharmaceutical Overdose Fatalities. *JAMA*. 2008;300(22): 2613–2620. doi:10.1001/jama.2008.802. Yang Z, Wilsey B, Bohm M, et al. Defining Risk of Prescription Opioid Overdose: Pharmacy Shopping and Overlapping Prescriptions Among Long-Term Opioid Users in Medicaid. *The Journal of Pain*. 16(5): 445–453.

Paulozzi L, Kilbourne E, Shah N, et. al. A History of Being Prescribed Controlled Substances and Risk of Drug Overdose Death. *Pain Medicine*. 2012;13(1): 87–95. doi: 10.1111/j.1526-4637.2011.01260.x. https://www.ncbi.nlm.nih.gov/books/NBK458661/)

- The number of days supply for a prescription (stimulants only).
- The number of overlapping days for each drug type.
- Each metric is tallied across 4 timeframes of reference:
  - Most recent 2 months
  - Most recent 6 months
  - Most recent 180 days
  - Most recent 365 days
- 5. The time elapsed for any literature-based risk factor serves to decrease its contribution to the score. For example, 1,000 MME dispensed within the last month will elevate the score more than 1,000 MME dispensed one year ago.
- 6. The distribution of Narx Scores for patients found in a PDMP is approximated as follows<sup>5</sup>:
  - a. 78% score between 0 and 200
  - b. 6.7% score between 200 and 299
  - c. 5.3% score between 300 and 399
  - d. 6.5% score between 400 and 499
  - e. 3.4% score between 500 and 599
  - f. ~1% score between 600 and 999

The Narx Scores were designed such that:

- 1. Patients who are exposed to small amounts of medication with limited provider and pharmacy usage will have **lower scores (e.g., scores below 199).**
- Patients who are exposed to large amounts of medications in accordance with recommended guidelines<sup>6</sup> (single provider, single pharmacy, etc.) will have mid-range scores (e.g., scores between 200 and 500).
- 3. Patients who are exposed to large amounts of medications while using many providers and pharmacies, and with frequently overlapping prescriptions, will have **higher scores** (e.g., scores above 500).

#### Narx Score Algorithm

#### **Relative Scoring**

Narx Scores represent a *relative scoring* system for a given patient's exposure to a controlled substance compared to the rest of the PDMP population. The literature-based risk factors listed above in the introduction of this section are quantified and then converted to a reference value, which ranges from 0–99. These reference values correlate with a percentile measurement of that exposure within the specified PDMP population.

<sup>&</sup>lt;sup>5</sup> This distribution is based on data obtained from a single state between 2017 – 2023 and may vary slightly depending on a patient's state of residence. <sup>6</sup> <u>https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm#Recommendation9</u>

•	Patient A:	160 MME
•	Patient B:	4,800 MME
٠	Patient C:	1,050 MME

A single point of measurement for total MME in the last 60 days can be used to illustrate this concept further using the following three patients:

If we were to place these three patients on a line representing relative exposure risk (e.g., based upon the presence of increasing opioid dose), we could imagine a linear relationship based on MME, which could be depicted as follows:



This depiction has no boundaries to the left or right so these patients could also be drawn as follows:



The Narx Score algorithm establishes boundaries of exposure by converting all measured variables, such as 60-day MME, to a scaled value between 0 and 99. This was done by evaluating each variable across each PDMP population and measuring the 60-day MME value for every patient with available data in the PDMP.

This set of data was then used to create a reference table roughly equating to a percentile in the population. If we add the scaled value to each example patient's 60-day MME, the result is:

	Raw Value	Scaled Value
Patient A:	160 MME	20
Patient B:	4,800 MME	90
Patient C:	1,050 MME	65

If we apply these new scaled values to our percentile-ranked risk diagram and create a left and right boundary of 0 and 99, the result is:



The percentile-ranked scaled values indicate that Patient B and C are closer to each other than might otherwise be suspected. In this case, we can also say that Patient B has used more MME in the last 60 days than 90% of the rest of the PDMP population in the PDMP where the patient resides.

#### **Time Periods**

The NarxCare algorithm evaluates a PDMP data record using four different, overlapping time periods. In each time period, the factor being evaluated is tabulated and then converted to a percentile-ranked scaled value. These reference tables exist for all the factors being evaluated and cover all four time periods. In general, as the raw value count (i.e., number of prescribers) increases, so does the reference value (up to 99 maximum). As the time period increases, the scaled value decreases, so older records contribute less to the score than more recent records with the same drug content.

#### Example provider reference tables are provided on the next page.

Prescriber Count	2mo Scaled	6mo Scaled	1 yr Scaled	2yr Scaled
0	0	0	0	0
1	19	12	8	6
2	36	22	16	11
3	51	32	23	16
4	64	41	30	21
5	75	49	37	26
6	85	57	43	30
And so on				

Pharmacy Count	2mo Scaled	6mo Scaled	1 yr Scaled	2yr Scaled
0	0	0	0	0
1	25	16	13	10
2	45	31	25	19
3	63	44	35	27
4	78	56	45	35
5	90	67	54	42
6	99	76	62	49
And so on				

Overlap Days	2mo Scaled	6mo Scaled	1 yr Scaled	2yr Scaled
0	0	0	0	0
1	3	2	1	1
2	6	4	3	2
3	9	5	4	3
4	11	7	6	4
5	14	9	7	5
6	16	10	8	6
And so on				

Copyright © 2023 Bamboo Health, Inc. All rights reserved.

Do not copy or distribute without the express written permission of Bamboo Health.

Sedative LME	2mo Scaled	6mo Scaled	1 yr Scaled	2yr Scaled
0	0	0	0	0
1-4	4	6	8	10
5 - 9	8	10	13	16
10 - 14	10	12	16	19
15 - 19	20	20	23	26
20 - 24	23	23	26	29
25 - 29	24	23	26	30
And so on				

#### Weighting

A Narx Score is calculated as a weighted average of the scaled values. A 50% weighting is applied to the milligram equivalencies with the remaining factors making up the other 50%.<sup>7</sup>



This type of weighting results in several relationships. If we think of milligram equivalency as *consumption* and the combination of providers, pharmacies, and overlaps collectively as *behaviors*, we can create the following score categories.

	<u>Consumption</u>	<u>Behaviors</u>	Narx Score
Patient A	Low	Low	Low
Patient B	Low	High	Mid
Patient C	High	Low	Mid
Patient D	High	High	High

It is important to understand that there are several different patterns of use that can result in the same score. It is <u>always</u> necessary to look at the actual PDMP data to determine what use patterns exist that have resulted in the Narx Score presented.

**CAUTION / IMPORTANT REMINDER**: Clinicians use Narx Scores as indicators to further review details in the patient's prescription history while attending to their patients. Narx Scores are intended to aid, not replace, medical decision-making. None of the information presented should be used as sole justification for providing or refusing to provide medications.

<sup>&</sup>lt;sup>7</sup> https://www.ncbi.nlm.nih.gov/books/NBK458661/

#### Score Computation

The following steps are involved in calculating a Narx Score:

- 1. Determine the raw values for all time periods for all variables.
- 2. Convert all raw values to scaled values.
- 3. Average the scaled values for each factor for all time periods.
- 4. Determine the weighted average.

**Note:** Dividing by the sum of the weights is necessary to normalize the weighted average. The weights used to calculate the average reflect the importance or significance of each feature, but they may not necessarily add up to 1.0 or 100%. By dividing the sum of the weighted features by the sum of the weights, we are essentially calculating the weighted average as a percentage of the total weight. This normalization ensures that the resulting average is on a scale of 0 to 1, or 0% to 100%, which makes it easier to compare the average across different datasets or to interpret it in a meaningful way. Without normalization, the weighted average could be misleading, especially if the weights are not proportional to each other or if the sum of weights is significantly different from the expected value of 1.0 or 100%.

5. Sum the number of active prescriptions and then concatenate to the two-digit percentile score.

# Using a sample patient for a hypothetical scaled value to illustrate the calculation of a Narcotic Score:

	60 days	6 mos.	1 year	2 years
Prescribers	6	9	15	15
Pharmacies	4	4	6	6
MME	1640	5408	7358	7364
LME	0	0	0	0
Overlaps	17	55	65	65

1. Determine the raw values for all time periods for all variables.

2. Convert all raw values to scaled values.

	60 days	6 mos.	1 year	2 years
Prescribers	85	76	84	64
Pharmacies	78	56	62	49
MME	74	87	88	87
LME	0	0	0	0
Overlaps	41	70	64	52

3. Average the scaled value for each factor for all time periods.

	60 days	6 mos.	1 year	2 years	Avg
Prescribers	85	76	84	64	77
Pharmacies	78	56	62	49	61
MME	74	87	88	87	84
LME	0	0	0	0	0
Overlaps	41	70	64	52	57

Copyright © 2023 Bamboo Health, Inc. All rights reserved.

Do not copy or distribute without the express written permission of Bamboo Health.

4. Calculate the weighted average.

	60 days	6 mos.	1 year	2 years	Avg	Wt.	
Prescribers	85	76	84	64	77	1	77
Pharmacies	78	56	62	49	61	1	61
MME	74	87	88	87	84	3	252
LME	0	0	0	0	0	1	0
Overlaps	41	70	64	52	56	2	114
Weighted Average (sum/8)						63	

5. Sum the number of active prescriptions and then concatenate to the two-digit percentile score.

	60 days	6 mos.	1 year	2 years	Avg	Wt.	
Prescribers	85	76	84	64	77	1	77
Pharmacies	78	56	62	49	61	1	61
MME	74	87	88	87	84	3	252
LME	0	0	0	0	0	1	0
Overlaps	41	70	64	52	56	2	114
Weighted Average (sum/8)						63	
Number of Active Narcotic Prescriptions					<u>2</u>		
Narcotic Score						63 <u>2</u>	

#### **General Considerations for Narx Scores**

Just as there is no single blood pressure that can be considered *normal* for all people, there is no single Narx Score that is considered *normal*. A Narx Score must be applied to the clinical scenario by the clinician. For example, a blood pressure of 120/80 can simultaneously be:

- Inappropriate for a 2-month-old infant
- Appropriate for a 20-year-old woman
- Inappropriate for an elderly patient with an average daily blood pressure of 200/100

#### Example Use Cases<sup>8</sup>

How Narx Scores, used in concert with additional information, can help to support discussions with patients:

• **Case A** – An 18-year-old male basketball player with other significant history presents with a severe ankle sprain. His Narx Scores are:

<u>Narcotic</u>	<u>Sedative</u>	<u>Stimulant</u>
000	000	000

**Important consideration:** If considered for a controlled substance due to the severity of injury, this maybe the patient's first exposure to the effects of a controlled substance. The clinician would typically conduct a thorough review of the risks and benefits with the patient.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917208/#:~:text=Similarly%2C%20the%20greatest%20share%20of,%E2%89%A565%20years%20(34.6%25)

• **Case B** – an 81-year-old female presents with decreased level of consciousness following a fall where she suffered a closed head injury. Her Narx Scores are:

Narcotic	<u>Sedative</u>	<u>Stimulant</u>
341	501	000

**Important Consideration:** Many elderly patients are on chronic opioids and benzodiazepines. The physician may want to consider whether this patient's use of opioids and benzodiazepines contributed to her fall. Alternatively, the physician may want to consider whether the patient may be taking too much medication and has potentially developed anxiety seizures due to benzodiazepine withdrawal, complicating the patient's medical picture.

 Case C – A 36-year-old male patient with mild chronic back pain frequently treated with controlled substances presents for a medication refill. Upon review of the patient's PDMP record, the patient has been to 17 different prescribers in the last year. His Narx Scores are:

<u>Narcotic</u>	<u>Sedative</u>	<u>Stimulant</u>
671	240	000

**Important Consideration:** Many patients obtain medications through multiple different providers. This can be due to the patient being seen in a clinic that is staffed by different providers, or it can be due to access to care issues requiring visits to urgent care centers or emergency departments.

 Case D – A 46-year-old female patient with chronic anxiety, frequently treated with benzodiazepines, presents for a medication refill. On review of the PDMP record, the attending physician notes that her Narcotic score is non-zero, yet her PDMP history does not show that narcotics were ever dispensed. Her Narx Scores are:

Narcotic	<u>Sedative</u>	<u>Stimulant</u>
30	30	000

#### Important Consideration:

- If a provider were to focus on the Narcotic score in isolation, this could lead to an
  incomplete view of a patient's current medication regimen. Therefore, with this
  type of patient in mind, Narx Scores incorporate an 'awareness value' for
  attending providers. For example, the literature is clear on the association
  between adverse events such as respiratory depression, sedation and drowsiness,
  central nervous system depression, as well as an increased risk of falls and injuries
  due to the concomitant use of narcotics and sedatives (which includes
  benzodiazepines).
- Thus, patients who only use narcotics (i.e., opioids) will receive a Sedative score to increase provider awareness that prescribing the latter drug type might elevate the likelihood of an adverse event. Similarly, patients who only use sedatives receive a Narcotic score to increase provider awareness that prescribing controlled substances might elevate the likelihood of an adverse event.
- Appropriate prescribing practices encourage this more holistic view.

CAUTION / IMPORTANT REMINDER: Clinicians use Narx Scores as indicators to further review details in the patient's prescription history while attending to their patients. Narx Scores are intended to aid, not replace, medical decision-making. None of the information presented should be used as sole justification for providing or refusing to provide medications.

## **Overdose Risk Score**

The NarxCare application also provides a composite index of discrete data obtained from the PDMP called an **Overdose Risk Score (ORS)**. The ORS is comprised of three digits ranging from 000–999.

**NOTICE REGARDING ORSv2**: The below materials describe the generally available version of ORS ("v1"). If you are among the users who have access to the new ORS model (currently called ORS "v2"), please refer to the separate background materials for v2. v2 has been in development since 2021 and has been updated to include different variables and weighting as an indicator of unintentional overdose death risk in light of the evolving epidemic. Recent tests on a validation dataset confirmed increased performance of v2. We encourage users to inquire about changing models to v2.

#### **ORS** Intended Use

ORS was developed with a logistic regression model using PDMP data as an input and is intended to provide an indicator, along with other patient-centric factors outlined below, for clinicians of the likelihood of an unintentional overdose death.

*Note:* ORS is meant to help aid in independent clinical decision-making by healthcare providers and is not intended for use by law enforcement agencies or activities, or any other uses.

#### **ORS** Algorithm Development

The ORS algorithm was derived using a common machine learning model (i.e., logistic regression) with a case-control study design. The model was originally trained using data obtained from over 5,000 autopsy adjudicated unintentional overdose deaths, which were age and gender-matched to 500,000 patients using prescribed controlled substances during the same time frame who did not experience an overdose death.

The training dataset was acquired from a state in the Midwest and spanned the years from 2013 to 2016. It included cases from both males (68%) and females (32%), with ages from 18 to 85, from both urban (94.38%) and rural (5.2%) demographics.

The training dataset produced the following validation statistics, odds ratios and score distribution.

#### Validation Statistics

- Precision (i.e., positive predictive value/true positive rate): 75%
- Recall (i.e., sensitivity): 57%
- Specificity (i.e., true negative rate): 81%
- Negative predictive value: 66%.

#### **Odds Ratios**

ORS	Number of Decedents	Number of Non-Decedents	Odds Ratio of Unintentional Overdose Death	Odds Ratio 95% Confidence Interval
000-199	1,108	193,636	1	ref
200–299	1,669	258,183	1.1	1.1-1.2
300–399	938	47,698	3.4	3.2-3.8
400–499	702	16,357	7.5	6.8-8.3
500–599	438	6,200	12.4	11.0-13.8
600-699	259	2,347	19.3	16.7-22.2
700-799	101	634	27.9	22.3-34.5
800-999	32	192	29.3	19.7-42.2

#### **Score Distribution**

- 000-199: 36.7%
- 200-299: 48.9%
- 300-399: 9.2%
- 400-499: 3.2%
- 500-599: 1.3%
- 600-999: 0.7%

#### Additional ORS External Validation

Additional validation of the model has been completed using decedent data from a different state than the training data state. The additional validation dataset spanned the years from 2017 to 2023 and contained ~ 400 decedents and ~ 32,000 non-decedents<sup>9</sup>, whose patient attributes were similar to those in the original training dataset. The validation data is a meaningfully smaller dataset, which can have a significant impact on the results in ORS bands with a small number of decedents. Thus, the smaller sample size resulted in a very small number of patients with a score >= 700.

Unlike the training dataset, this dataset comes from the period of time during which there was widespread acceptance and use of medications for opioid use disorder (MOUDs) impacting ORS MME calculations, as described below, and death rates. During this time period, illicit opiates, which are not tracked in the PDMP (and therefore not included in the ORS model), became a much larger cause of overdose death. Therefore, ORS provides an indicator of the rare event of an unintentional overdose death (in the context of all patients in the PDMP) using data from controlled substances that are less likely to be involved in the event than when ORS was developed.

<sup>&</sup>lt;sup>9</sup> Rounded to the nearest 100.

The additional validation dataset produced the following validation statistics, odds ratios and score distribution.

#### Validation Statistics

- Precision (i.e., positive predictive value/true positive rate): 52%
- Recall (i.e., sensitivity): 63%
- Specificity (i.e., true negative rate): 41%
- Negative predictive value: 53%.

*Note:* We plan to update these metrics with additional data from other states with larger sample sizes.

#### Odds Ratios

*Note:* Numbers in each score category in the Table below have been rounded to preserve the anonymity of the validation dataset and maintain the original odds ratios

ORS	Number of Decedents	Number of Non-Decedents	Odds Ratio of Unintentional Overdose Death	Odds Ratio 95% Confidence Interval
000-199	210	21,000	1	ref
200–299	90	6,000	1.5	1.2-1.9
300–399	45	2,900	1.6	1.1-2.1
400–499	20	1,300	1.6	0.9-2.4
500–599	22	500	4.4	2.7-6.8
600-999	13	300	4.4	2.3-7.5

#### **Score Distribution**

- 000-199:66.4%
- 200-299: 19.1%
- 300-399: 9.2%
- 400-499: 4.1%
- 500-599: 1.6%
- 600-999: 0.9%

#### **ORS** Data Inputs

Data quality of ORS data inputs is maintained by having the PDMP data renormalized with the most up-to-date source data. ORS inputs the most current information available from the PMDP. Data quality is maintained by re-running a number of fields against the source files. To create labels for the training and validation data, decedent records were matched to PDMP data using a proprietary patient name matching system that connects dispensation records to each deceased patient.

The accuracy of any predictive model is impacted by the data input. In the case of ORS, the data is pulled from government managed and regulated PDMPs. Therefore, the data input for ORS is the same data that a user can access by reviewing the details in the PDMP report. The data used in ORS is matched to the patient using the same processes employed throughout NarxCare.

The nine data inputs into the ORS algorithm are listed below and are all obtained from PDMP data. All data inputs are required for analysis, and are listed in order of their weighted relevance, with the first having the highest relevance at approximately 25-30% and the last three weighted the least at <1%:

- 1. Total Morphine Milligram Equivalent (MMEs) prescribed during the most recent 365 days (including MMEs from MOUDs when dispensed to the patient);
- 2. Number of pharmacies where narcotics and/or sedatives were filled in the last 2 years;
- 3. Total MMEs prescribed during in the last 2 years (including MMEs from MOUDs when dispensed to the patient);
- Controlled substance prescriptions with daily MMEs >120 in the last 2 years (including MMEs from MOUDs);
- 5. Total dosage (milligrams) of sedatives prescribed during the last 2 years;
- 6. Number of prescribers where narcotics/sedatives were obtained in the last 2 years;
- 7. Total dosage (milligrams) of sedatives prescribed for 1 or more years prior to the current date;
- 8. Total MMEs prescribed for 1 or more years prior to the current date (including MMEs from MOUDs); and
- 9. Number of prescribers where narcotics/sedatives were obtained in the last 180 days.

**NOTE:** If one or more of these elements is not available for a patient, the ORS score is not calculated and will not be presented to the healthcare provider. Stimulants are not included within the inputs. As stated above, MMEs from MOUDs are included in several inputs. MOUDs may have high MMEs relative to other controlled substances and thus have meaningful impact on the model results. Clinicians should be mindful of that impact and review the prescription details to further understand MOUD inputs.

As noted above, the ORS takes multiple PDMP factors into consideration for risk of unintentional overdose death and is more predictive than any one factor.

#### Additional Information on ORS

ORS is intended to provide a multi-variable indicator of unintentional overdose death risk based on PDMP data. The ORS algorithm does not incorporate any data other than what is available in the PDMP. This aligns the clinical application of the score with other sources of overdose risk assessment based on PDMP data such as number of pharmacies visited in the last 90 days or daily morphine equivalent dose (MED). Since the original release of ORS v1, prescribing patterns have evolved due to many factors. In particular, there has been increasing acceptance, and therefore, more widespread use of MOUDs. This change is reflected in the datasets. The prevalence of MOUD use in the original training dataset spanning 2013-2016 was 7% among decedents, whereas the prevalence of MOUD use among decedents in the validation dataset spanning 2017-2023, was 23%. This represents a non-trivial change in prescribing patterns over time and can significantly impact a patient's ORS, given that Buprenorphine formulations may have high MMEs, and MME is a component of several predictive features of the current ORS model.

**CAUTION / IMPORTANT REMINDER**: Clinicians use Overdose Risk Scores as indicators to further review details in the patient's prescription history while attending to their patients. Overdose Risk Scores are intended to aid, not replace, medical decision-making. Other patient-centric factors, such as mental health conditions<sup>10</sup> (e.g., depression, anxiety, bipolar disorder, dementia), substance use conditions<sup>11</sup>, respiratory conditions<sup>12</sup>, hepatic and renal conditions<sup>13</sup>, and history of overdose,<sup>14</sup> may influence unintentional overdose death but are not incorporated in the PDMP data used to calculate the Overdose Risk Score. None of the information presented should be used as sole justification for providing or refusing to provide medications.

11

<sup>&</sup>lt;sup>10</sup> van Draanen J, Tsang C, Mitra S, Phuong V, Murakami A, Karamouzian M, Richardson L. Mental disorder and opioid overdose: a systematic review. Soc Psychiatry Psychiatr Epidemiol. 2022 Apr;57(4):647-671. doi: 10.1007/s00127-021-02199-2. Epub 2021 Nov 18. PMID: 34796369; PMCID: PMC8601097

https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2011.10101476#:~:text=Analyses%20suggest%20that%20individuals%20who.with%20individuals%20who

<sup>&</sup>lt;sup>12</sup> Le TT, Park S, Choi M, *et al*Respiratory events associated with concomitant opioid and sedative use among Medicare beneficiaries with chronic obstructive pulmonary disease *BMJ Open Respiratory Research* 2020;**7**:e000483. doi: 10.1136/bmjresp-2019-000483

<sup>&</sup>lt;sup>13</sup> Bohnert ASB, Valenstein M, Bair MJ, et al. Association Between Opioid Prescribing Patterns and Opioid Overdose-Related Deaths. *JAMA*. 2011;305(13):1315–1321. doi:10.1001/jama.2011.370

<sup>&</sup>lt;sup>14</sup> Caudarella A, Dong H, Milloy MJ, Kerr T, Wood E, Hayashi K. Non-fatal overdose as a risk factor for subsequent fatal overdose among people who inject drugs. Drug Alcohol Depend. 2016 May 1;162:51-5. doi: 10.1016/j.drugalcdep.2016.02.024. Epub 2016 Feb 26. PMID: 26993373; PMCID: PMC4833586

# **Document Information**

# Disclaimer

Bamboo Health has made every effort to ensure the accuracy of the information in this document at the time of printing. However, information is subject to change.

# Change Log

Version	Date	Chapter/Section	Change Made
1.0	9/14/2023	N/A	N/A; initial publication